Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers
Aim: To evaluate the impact of prescription, cost, and switching policy on the rate of switching from reference products to biosimilars. Methods: Analysis of an administrative database for prescription in a rheumatology division. Biosimilars for adalimumab and etanercept were available in 2019. Blin...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2024-09-01
|
| Series: | Exploration of Musculoskeletal Diseases |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100764/100764.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729688597954560 |
|---|---|
| author | Fernando Perez-Ruiz Elena Garmendia-Sanchez Javier Arostegui-Lavilla Javier Duruelo-Echevarrieta Joana Atxotegi-Saenz de Buruaga Mayra Nathali Rivas-Zavaleta Javier Casas-Arrate Maria del Consuelo Modesto-Caballero Amaya de Basagoiti-Gorordo |
| author_facet | Fernando Perez-Ruiz Elena Garmendia-Sanchez Javier Arostegui-Lavilla Javier Duruelo-Echevarrieta Joana Atxotegi-Saenz de Buruaga Mayra Nathali Rivas-Zavaleta Javier Casas-Arrate Maria del Consuelo Modesto-Caballero Amaya de Basagoiti-Gorordo |
| author_sort | Fernando Perez-Ruiz |
| collection | DOAJ |
| description | Aim: To evaluate the impact of prescription, cost, and switching policy on the rate of switching from reference products to biosimilars. Methods: Analysis of an administrative database for prescription in a rheumatology division. Biosimilars for adalimumab and etanercept were available in 2019. Blinded costs and prescription data were not shared with prescribing physicians until 2021. The rate of prescription, persistence of therapy after switching, and reduction of cost were analyzed from 2019 to 2022. A new etanercept biosimilar was prioritized in 2022, and a new switching wave from biosimilar to biosimilar etanercept was implemented. Results: Overall switching from 2019 to 2022 comprised 132/135 (97.8%) of patients. The rate of switching increased from 13.3% to 34%, 79%, and 95.5% of patients on reference products during 2019, 2020, 2021, and 2022, respectively. In 2022, after sharing information, the switch comprised 55/135 (40.7%) of overall switching. The rate of persistence on therapy after switching was 86.8% for etanercept and 79.7 for adalimumab. During 2023, a rate of 76.6% switching etanercept reference-biosimilar-biosimilar was achieved. The reduction in the overall biologic budget in 2021 was 19.2% and 29.0% for the patient-year cost. Conclusions: Information to prescribers may improve switching policies. Persistence on biosimilar medications after switching is as high as previously reported. |
| format | Article |
| id | doaj-art-6a235ba8f62a4670a2fb73be06ad4c87 |
| institution | DOAJ |
| issn | 2836-6468 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Musculoskeletal Diseases |
| spelling | doaj-art-6a235ba8f62a4670a2fb73be06ad4c872025-08-20T03:09:08ZengOpen Exploration Publishing Inc.Exploration of Musculoskeletal Diseases2836-64682024-09-012538439010.37349/emd.2024.00064Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribersFernando Perez-Ruiz0https://orcid.org/0000-0002-5268-1894Elena Garmendia-Sanchez1Javier Arostegui-Lavilla2Javier Duruelo-Echevarrieta3Joana Atxotegi-Saenz de Buruaga4Mayra Nathali Rivas-Zavaleta5Javier Casas-Arrate6Maria del Consuelo Modesto-Caballero7https://orcid.org/0000-0002-4983-5506Amaya de Basagoiti-Gorordo8https://orcid.org/0000-0003-0894-9539Osakidetza, OSI-EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, Spain; University of the Basque, Medicine and Nursery School, Medicine Department, Country Cruces Teaching Unit, 48903 Barakaldo, SpainOsakidetza, OSI-EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, SpainOsakidetza, OSI-EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, SpainOsakidetza, OSI-EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, SpainOsakidetza, OSI-EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, SpainOsakidetza, OSI-EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, SpainCruces University Hospital, Pharmacy Division, 48903 Barakaldo, SpainOsakidetza, OSI-EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, SpainCruces University Hospital, Pharmacy Division, 48903 Barakaldo, SpainAim: To evaluate the impact of prescription, cost, and switching policy on the rate of switching from reference products to biosimilars. Methods: Analysis of an administrative database for prescription in a rheumatology division. Biosimilars for adalimumab and etanercept were available in 2019. Blinded costs and prescription data were not shared with prescribing physicians until 2021. The rate of prescription, persistence of therapy after switching, and reduction of cost were analyzed from 2019 to 2022. A new etanercept biosimilar was prioritized in 2022, and a new switching wave from biosimilar to biosimilar etanercept was implemented. Results: Overall switching from 2019 to 2022 comprised 132/135 (97.8%) of patients. The rate of switching increased from 13.3% to 34%, 79%, and 95.5% of patients on reference products during 2019, 2020, 2021, and 2022, respectively. In 2022, after sharing information, the switch comprised 55/135 (40.7%) of overall switching. The rate of persistence on therapy after switching was 86.8% for etanercept and 79.7 for adalimumab. During 2023, a rate of 76.6% switching etanercept reference-biosimilar-biosimilar was achieved. The reduction in the overall biologic budget in 2021 was 19.2% and 29.0% for the patient-year cost. Conclusions: Information to prescribers may improve switching policies. Persistence on biosimilar medications after switching is as high as previously reported.https://www.explorationpub.com/uploads/Article/A100764/100764.pdfbiologicsbiosimilarsinterchangeabilityswitchingcost |
| spellingShingle | Fernando Perez-Ruiz Elena Garmendia-Sanchez Javier Arostegui-Lavilla Javier Duruelo-Echevarrieta Joana Atxotegi-Saenz de Buruaga Mayra Nathali Rivas-Zavaleta Javier Casas-Arrate Maria del Consuelo Modesto-Caballero Amaya de Basagoiti-Gorordo Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers Exploration of Musculoskeletal Diseases biologics biosimilars interchangeability switching cost |
| title | Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers |
| title_full | Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers |
| title_fullStr | Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers |
| title_full_unstemmed | Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers |
| title_short | Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers |
| title_sort | successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers |
| topic | biologics biosimilars interchangeability switching cost |
| url | https://www.explorationpub.com/uploads/Article/A100764/100764.pdf |
| work_keys_str_mv | AT fernandoperezruiz successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT elenagarmendiasanchez successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT javierarosteguilavilla successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT javierdurueloechevarrieta successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT joanaatxotegisaenzdeburuaga successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT mayranathalirivaszavaleta successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT javiercasasarrate successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT mariadelconsuelomodestocaballero successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers AT amayadebasagoitigorordo successfulimplementationofinterchangeofbiologicmedicationsinchronicarthritisafterinformationofcoststoprescribers |